CAL02 + Placebo

Phase 2Active
0 watching 0 views this week Active
44
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pneumonia, Bacterial

Conditions

Pneumonia, Bacterial

Trial Timeline

Jul 22, 2023 → Sep 7, 2026

About CAL02 + Placebo

CAL02 + Placebo is a phase 2 stage product being developed by Eagle Pharmaceuticals for Pneumonia, Bacterial. The current trial status is active. This product is registered under clinical trial identifier NCT05776004. Target conditions include Pneumonia, Bacterial.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05776004Phase 2Active

Competing Products

20 competing products in Pneumonia, Bacterial

See all competitors
ProductCompanyStageHype Score
CAL02 Low-dose + CAL02 High-dose + PlaceboCombioxinPhase 1
25
tacrolimusAstellas PharmaPre-clinical
23
Cefiderocol + Best Available TherapyShionogiPhase 3
77
Cefiderocol + Meropenem + LinezolidShionogiPhase 3
77
Cefiderocol + Standard of Care AntibioticShionogiPhase 1
33
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
52
doripenemJohnson & JohnsonApproved
85
levofloxacin; imipenem/cilastitinJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 2/3
65
LevofloxacinJohnson & JohnsonPhase 3
77
doripenemJohnson & JohnsonPhase 3
77
doripenemJohnson & JohnsonPhase 3
77
Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
77
Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + DoripenemJohnson & JohnsonPhase 2
52
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
52
Ceftazidime-avibactamAbbViePhase 1
33
Ticagrelor + PlaceboAstraZenecaPhase 2
52
Tedizolid phosphate + LinezolidMerckPhase 3
77
Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3
77